Amorim Hugo, Santoalha José, Cadilha Rui, Festas Maria-José, Barbosa Paula, Gomes Armanda
Centro Hospitalar de São João, Porto, Portugal.
Porto Biomed J. 2017 Nov-Dec;2(6):273-276. doi: 10.1016/j.pbj.2017.04.005. Epub 2017 May 19.
Chronic anal fissure is a common condition associated with intense pain.Local botulinum toxin injection is a valid option in its management.Pain intensity scores significantly improved after BoNT injection.Side effects were rare and mild.Our results support the inclusion of BoNT in the management algorithm of chronic anal fissure.
Chronic anal fissure is a common condition associated with intense pain. Local botulinum toxin injection is a valid option in its management. The purpose of this study was to evaluate the efficacy of botulinum toxin on pain relief in chronic anal fissure patients.
We conducted a retrospective cohort study, involving 81 consecutive patients referred to a chronic pain management unit due to a chronic anal fissure for treatment with botulinum toxin, during a 4 year period. Data were collected from hospital records regarding pre-treatment and post-treatment pain (numeric rating scale), side effects, need for botulinum toxin reinjection and need for surgical treatment. We used standard statistical methods for inter (-test and qui) and intra-group (paired sample -test) comparisons, according to variables distribution.
Pain intensity rest score significantly improved after BoNT injection [variation: -4.2 ± 2.9 ( < 0.001)], as did pain post-defecation score [variation: -5.1 ± 3.0 ( < 0.001)]. 8.6% needed botulinum toxin reinjection and 23.5% were submitted to surgery. Side effects were reported in 8.6%.
The efficacy of botulinum toxin use on pain reduction along with its non-permanent and minor side effects support its role in the resolution of chronic anal fissure. However, treatment failure in the long term is still significant.
Botulinum toxin is effective on pain relief in patients with chronic anal fissure, which supports its inclusion in the management algorithm of this condition.
慢性肛裂是一种伴有剧痛的常见病症。局部注射肉毒杆菌毒素是其治疗的有效选择。注射肉毒杆菌毒素后疼痛强度评分显著改善。副作用罕见且轻微。我们的结果支持将肉毒杆菌毒素纳入慢性肛裂的治疗方案中。
慢性肛裂是一种伴有剧痛的常见病症。局部注射肉毒杆菌毒素是其治疗的有效选择。本研究的目的是评估肉毒杆菌毒素对慢性肛裂患者缓解疼痛的疗效。
我们进行了一项回顾性队列研究,在4年期间,连续纳入81例因慢性肛裂转诊至慢性疼痛管理单元接受肉毒杆菌毒素治疗的患者。从医院记录中收集有关治疗前和治疗后疼痛(数字评分量表)、副作用、肉毒杆菌毒素再次注射需求和手术治疗需求的数据。根据变量分布,我们使用标准统计方法进行组间(t检验和方差分析)和组内(配对样本t检验)比较。
注射肉毒杆菌毒素后疼痛强度静息评分显著改善[变化:-4.2±2.9(P<0.001)],排便后疼痛评分也显著改善[变化:-5.1±3.0(P<0.001)]。8.6%的患者需要再次注射肉毒杆菌毒素,23.5%的患者接受了手术。8.6%的患者报告有副作用。
肉毒杆菌毒素在减轻疼痛方面的疗效及其非永久性和轻微副作用支持其在慢性肛裂治疗中的作用。然而,长期治疗失败率仍然较高。
肉毒杆菌毒素对慢性肛裂患者缓解疼痛有效,这支持将其纳入该病的治疗方案中。